Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26247169 | 0.87 | TSHR (0.50) | TSHRSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL22481046 | 0.82 | TSHR (0.52) | TSHRSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL8229657 | 0.82 | TSHR (0.46) | TSHRSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL5648725 | 0.81 | TSHR (0.58) | TSHRSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL16956895 | 0.81 | TSHR (0.46) | TSHRSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL305927 | 0.81 | ALDH1A1 (0.44) | TSHRSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL305926 | 0.81 | ALDH1A1 (0.44) | TSHRSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL29959661 | 0.80 | TSHR (0.70) | TSHRSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL14933431 | 0.80 | TSHR (0.56) | TSHRSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL307312 | 0.80 | TSHR (0.70) | TSHRSMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183415-B2 | Quinoline compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7183415-B2 | Quinoline compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7183415-B2 | Quinoline compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| CN-1286815-C | 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2006-11-29 | — | — | CN | disclosed |
| US-20060173034-A1 | Novel 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | US | disclosed |
| US-7037925-B2 | 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2006-05-02 | — | — | US | disclosed |
| US-20050209213-A1 | Quinoline compound | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| CN-1585751-A | Quinoline compound | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-02-23 | — | — | CN | disclosed |
| US-20040248923-A1 | Novel 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | US | disclosed |
| EP-1447402-A1 | QUINOLINE COMPOUND | Takeda Chemical Industries, Ltd. (JP) | 2004-08-18 | — | — | EP | disclosed |
| CN-1507434-A | Novel 4-anilinoquinoline-3-carboxamides | — | 2004-06-23 | — | — | CN | disclosed |
| EP-1387830-A1 | NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES | AstraZeneca AB (SE) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002092571-A1 | NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248923-A1 | Novel 4-anilinoquinoline-3-carboxamides | JAK3, JAK2, JAK1 | TSHR 2999/4885SMN1; SMN2 4092/4885MEN1 3698/4885 |
| US-20060173034-A1 | Novel 4-anilinoquinoline-3-carboxamides | JAK3, JAK2, JAK1 | TSHR 2556/4885SMN1; SMN2 4300/4885MEN1 3584/4885 |
| US-20050209213-A1 | Quinoline compound | MC1R, MC2R, TYR | TSHR 162/4885SMN1; SMN2 3577/4885MEN1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.